Small Molecule targeting of NADPH oxidase in neutrophils
Small Molecule targeting of NADPH oxidase in neutrophils
批准号:
8003097
负责人:
Marie-Dominique Filippi
金额:
$31.87万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-08-01 至 2012-07-31
关键词:
2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole4-ethoxymethylene-2-phenyl-2-oxazoline-5-oneAcuteAcute DiseaseAcute Lung InjuryAdult Respiratory Distress SyndromeAdverse eventAffinityAmericasAnti-Inflammatory AgentsAnti-inflammatoryBindingBiological AssayBlood CellsCatalysisCell LineageCell SurvivalCell membraneCellsCessation of lifeChronicChronic Obstructive Airway DiseaseClinicalComplexCytoskeletonCytosolDataDevelopmentDiseaseDoseDrug Delivery SystemsDrug KineticsEdemaElectron TransportEventFluorescenceFree RadicalsFunctional disorderGene TargetingGenerationsGoalsGuanosine Triphosphate PhosphohydrolasesHumanIn VitroInflammationInflammatoryInflammatory ResponseInhibitory Concentration 50IsoenzymesLeadLungLung InflammationLung diseasesMembraneModalityMolecularMorbidity - disease rateMultiple TraumaMusNADPNADPH OxidaseNeutrophil ActivationNeutrophil InfiltrationOperative Surgical ProceduresOxidasesOxygenPermeabilityPharmaceutical PreparationsPharmacologic SubstancePhasePhenotypeProcessProductionReactive Oxygen SpeciesRegulationResearchRespiratory FailureSafetyScreening procedureSepsisSeveritiesSignal TransductionSmall Business Technology Transfer ResearchSpecificityStimulusSuperoxidesToxic effectToxicity TestsTransfusionTumor Necrosis Factor-alphaUnited StatesValidationchemokinecytochrome b558cytokinedesignefficacy testinghuman TNF proteinin vivoinhibitor/antagonistlung injurymigrationmortalitymouse modelneutrophilneutrophil cytosol factor 40Kneutrophil cytosol factor 67Knovelnovel therapeuticsprognosticprotein protein interactionpublic health relevanceresponsesmall moleculesuperoxide-generating NADPH oxidasetreatment site
中文摘要
描述(申请人提供):急性肺损伤(ALI)和急性呼吸窘迫综合征(ARDS)的特征是快速和严重的呼吸衰竭,出现在重大手术、创伤、多次输血和脓毒症等临床事件之后。ALI/ARDS的相关死亡率为40%-80%,目前的药物治疗在降低死亡率方面并不成功。ARDS、ALI(以及包括慢性阻塞性肺疾病(COPD)在内的其他呼吸道疾病)与中性粒细胞在气道壁的渗透有关。大量的观察和实验数据支持中性粒细胞与上述呼吸道疾病的严重程度和进展密切相关。这项研究的目标是开发一类针对中性粒细胞功能的新型抗炎药物,以改善包括急性肺损伤/急性呼吸窘迫综合征(ALI/ARDS)和慢性阻塞性肺疾病(COPD)在内的肺部疾病。我们建议开发针对Rac GTPase和Rac-p67Phox相互作用抑制剂的小分子抑制剂,以下调肺部疾病中的中性粒细胞功能。ARDS和ALI的主要临床表现是由内皮功能障碍和微血管通透性引起的水肿。这是由于活化的中性粒细胞渗入肺部释放自由基、活性氧基(ROS)和炎性细胞因子(例如,肿瘤坏死因子-1)造成的。ROS的产生是中性粒细胞NADPH超氧化物复合体激活的结果。NADPH超氧化物复合体由一个质膜结合的黄细胞素b558(Cyt B)和一个称为p47Phox-p67Phox-p40Phox的调节复合体组成,它位于中性粒细胞的胞浆中。P47Phox-p67Phox-p40Phox复合体响应炎症信号启动的Rac GTP酶激活而移位到膜上,产生超氧阴离子(O2-)和其他有害的氧自由基。激活的Rac GTP酶和p67Phox之间的直接相互作用是中性粒细胞炎症过程中的一个重要步骤,也是我们小分子先导化合物的靶点:1)NSC23766,选择性Rac GTP酶抑制剂;2)Phox-I,选择性p67Phox-I抑制剂。在初步研究中,我们已确定(1)在基因打靶研究中,Rac GTP酶rac1和rac2是中性粒细胞迁移和超氧化物产生的必不可少的调节者;(2)我们合理设计的Rac特异性小分子抑制剂NSC23766在功能上抑制了包括中性粒细胞在内的各种血细胞系的Rac活性;(3)我们的先导化合物Phox-I与p67Phox的RAC交互口袋结合,有效地抑制了原发中性粒细胞中的氧化酶活性;(4)fMLP诱导的肺炎症小鼠模型有助于筛选治疗急性和慢性炎症性肺部疾病的新化合物。因此,目前的第一阶段STTR提案侧重于利用我们对RAC GTP酶对NOX2 NADPH氧化酶分子调控的详细了解来开发治疗急、慢性肺部疾病的一流药物。它将在以下方面验证NSC23766和Phox-I的靶点:A)体外蛋白质相互作用研究,B)小鼠中性粒细胞研究和C)人中性粒细胞研究(AIM1);在体内测试毒性和药代动力学,并确定NSC23766和Phox-I在急性肺炎症小鼠模型(AIM2)中的疗效。长期目标是提供一种新的药物靶点,即RAC-p67Phox信号轴,以及针对这一关键信号位点的合适的先导化合物,用于治疗急性肺炎性疾病ALI/ARDS。
公共卫生相关性:急性肺损伤(ALI)和急性呼吸窘迫综合征(ARDS)是严重的呼吸衰竭,发生在重大手术、创伤、多次输血和脓毒症等临床事件之后。一般而言,肺呼吸道疾病是美利坚合众国发病率和死亡率的主要原因之一。ALI/ARDS的相关死亡率为40%-80%,目前的药物治疗在降低死亡率方面并不成功。因此,开发治疗肺部疾病的新疗法至关重要。ALI和ARDS与中性粒细胞相关炎症升高有关。目前的第一阶段STTR提案将测试我们开发的两种中性粒细胞功能小分子抑制剂对肺部炎症性疾病的疗效。因此,我们的研究将有助于提供一个新的药物靶点,以及合适的先导化合物来治疗肺部炎症,如ALI和ARDS。
英文摘要
DESCRIPTION (provided by applicant): Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are characterized by a rapid and severe respiratory failure, arising after clinical events including major surgery, trauma, multiple transfusions and sepsis. ALI/ARDS have an associated mortality of 40-80% and current pharmacological modalities have been unsuccessful in decreasing mortality. ARDS, ALI (and other airway diseases including the Chronic Obstructive Pulmonary Disease (COPD)) are associated with neutrophil infiltration of the airway wall. Considerable observational and experimental data support a tight correlation between neutrophils and the severity and progression of the above airways diseases. The goal of the proposed research is to develop a novel class of anti-inflammatory drugs specifically targeting neutrophil functions for amelioration of lung diseases including acute lung injury/acute respiratory distress syndrome (ALI/ARDS) and chronic obstructive pulmonary disease (COPD). We propose to develop small molecule inhibitors that target Rac GTPase and Rac-p67phox interaction inhibitors to downmodulate neutrophil functions in lung diseases. The principal clinical manifestation of ARDS and ALI is edema, which results from endothelial dysfunction and microvasculature permeability. This is caused by release of free radical and reactive oxygen species (ROS) and inflammatory cytokines (e.g., TNF-1) from the activated neutrophils infiltrating the lungs. ROS production results from the activation of the neutrophil NADPH superoxide complex. The NADPH superoxide complex consists of a plasma membrane-bound flavocytochrome b558 (cyt b) and a regulatory complex, termed p47phox-p67phox-p40phox, taht is located in the cytosol of neutrophils. The p47phox-p67phox- p40phox complex translocates to the membrane in response to inflammatory signal-initiated Rac GTPase activation to produce superoxide anion (O2-) and other deleterious oxygen radicals. The direct interaction between activated Rac GTPase and p67phox is an essential step in this neutrophil inflammatory process and are the targets for our small molecule lead compounds: 1) NSC23766, a selective Rac GTPase inhibitor, and 2) phox-I, a selective p67phox inhibitor phox-I. In preliminary studies, we have established that (1) the Rac GTPases, Rac1 and Rac2, are essential regulators of neutrophil migration and superoxide production in gene targeting studies, (2) our rationally designed Rac-specific small molecule inhibitor, NSC23766, functionally suppressed Rac activity in various blood cell lineages including neutrophils, (3) our lead compound, phox-I, binds to the Rac interactive pocket of p67phox and is effective in suppressing oxidase activity in primary neutrophils, and (4) a fMLP-induced lung inflammation mouse model is useful for screening novel compounds for treating both acute and chronic lung inflammatory disorders. Thus, the present Phase I STTR proposal focuses on utilizing our detailed understanding of the molecular regulation of NOX2 NADPH oxidase by Rac GTPases to develop first-in-class treatments for acute and chronic lung disorders. It will validate the target of NSC23766 and phox-I in: A) in vitro protein-protein interaction studies, B) mouse neutrophil studies and C) human neutrophil studies (Aim1); test toxicity and pharmacokinetics in vivo and determine the efficacy of NSC23766 and phox-I in acute lung inflammation mouse model (Aim2). The long term goal is to deliver a novel pharmaceutical target, the Rac-p67phox signaling axis, and suitable lead compounds targeting this key signaling site, for the treatment of acute lung inflammatory disorders ALI/ARDS.
PUBLIC HEALTH RELEVANCE: Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are severe respiratory failure, arising after clinical events including major surgery, trauma, multiple transfusions and sepsis. In general, lung airway diseases are amongst the leading causes of morbidity and mortality in the United States of America. ALI/ARDS have an associated mortality of 40-80% and current pharmacological modalities have been unsuccessful in decreasing mortality. It is thus critically important to develop new therapies for the treatment of lung diseases. ALI and ARDS are associated with elevated neutrophil-related inflammation. The present Phase I STTR proposal will test the efficacy of two small molecule inhibitors of neutrophil functions that we have developed, on lung inflammatory disorders. Therefore, our study will help delivering a novel pharmaceutical target, and suitable lead compounds for the treatment of lung inflammation, such as ALI and ARDS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of mitochondria in hematopoietic stem cell self-renewal
-
批准号:10544162
-
项目类别:
-
资助金额:$60.36万
-
财政年份:2021
-
负责人:Marie-Dominique Filippi
-
依托单位:
The role of mitochondria in hematopoietic stem cell self-renewal
-
批准号:10320951
-
项目类别:
-
资助金额:$60.69万
-
财政年份:2021
-
负责人:Marie-Dominique Filippi
-
依托单位:
Single Cell Characterization and Procurement Core
-
批准号:10201888
-
项目类别:
-
资助金额:$24.02万
-
财政年份:2021
-
负责人:Marie-Dominique Filippi
-
依托单位:
The role of mitochondria in hematopoietic stem cell self-renewal
-
批准号:10116536
-
项目类别:
-
资助金额:$61.51万
-
财政年份:2021
-
负责人:Marie-Dominique Filippi
-
依托单位:
Single Cell Characterization and Procurement Core
-
批准号:10673652
-
项目类别:
-
资助金额:$24.02万
-
财政年份:2021
-
负责人:Marie-Dominique Filippi
-
依托单位:
Single Cell Characterization and Procurement Core
-
批准号:10458593
-
项目类别:
-
资助金额:$24.02万
-
财政年份:2021
-
负责人:Marie-Dominique Filippi
-
依托单位:
Regulation of functionally discrete hematopietic stem cells
-
批准号:10544722
-
项目类别:
-
资助金额:$57.45万
-
财政年份:2020
-
负责人:Marie-Dominique Filippi
-
依托单位:
Regulation of functionally discrete hematopietic stem cells
-
批准号:9886000
-
项目类别:
-
资助金额:$59.21万
-
财政年份:2020
-
负责人:Marie-Dominique Filippi
-
依托单位:
Regulation of functionally discrete hematopietic stem cells
-
批准号:10319603
-
项目类别:
-
资助金额:$57.97万
-
财政年份:2020
-
负责人:Marie-Dominique Filippi
-
依托单位:
Regulation of hematopoietic stem cell self-renewal by GTPase activating protein signaling
-
批准号:9096081
-
项目类别:
-
资助金额:$42.03万
-
财政年份:2015
-
负责人:Marie-Dominique Filippi
-
依托单位:
Regulation of hematopoietic stem cell self-renewal by GTPase activating protein signaling
-
批准号:8987948
-
项目类别:
-
资助金额:$42.63万
-
财政年份:2015
-
负责人:Marie-Dominique Filippi
-
依托单位:
Regulation of hematopoietic stem cell self-renewal by GTPase activating protein signaling
-
批准号:9312256
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2015
-
负责人:Marie-Dominique Filippi
-
依托单位:
Molecular Regulation of Neutrophil Transcellular Migration'
-
批准号:8961440
-
项目类别:
-
资助金额:$30.81万
-
财政年份:2015
-
负责人:Marie-Dominique Filippi
-
依托单位:
Regulation of Hematopoietic Stem Cell Self Renewal
-
批准号:8113186
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2010
-
负责人:Marie-Dominique Filippi
-
依托单位:
Regulation of Neutrophil Migration and Polarity
-
批准号:8228010
-
项目类别:
-
资助金额:$37.87万
-
财政年份:2010
-
负责人:Marie-Dominique Filippi
-
依托单位:
Regulation of Neutrophil Migration and Polarity
-
批准号:8435482
-
项目类别:
-
资助金额:$36.05万
-
财政年份:2010
-
负责人:Marie-Dominique Filippi
-
依托单位:
Regulation of Neutrophil Migration and Polarity
-
批准号:8616776
-
项目类别:
-
资助金额:$37.11万
-
财政年份:2010
-
负责人:Marie-Dominique Filippi
-
依托单位:
Regulation of Neutrophil Migration and Polarity
-
批准号:8035442
-
项目类别:
-
资助金额:$38.21万
-
财政年份:2010
-
负责人:Marie-Dominique Filippi
-
依托单位:
Regulation of Neutrophil Migration and Polarity
-
批准号:7784655
-
项目类别:
-
资助金额:$38.04万
-
财政年份:2010
-
负责人:Marie-Dominique Filippi
-
依托单位:
Regulation of Hematopoietic Stem Cell Self Renewal
-
批准号:7979318
-
项目类别:
-
资助金额:$22.88万
-
财政年份:2010
-
负责人:Marie-Dominique Filippi
-
依托单位: